ACRS (Aclaris Therapeutics) Insider Ownership: 3.16 % (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACRS Aclaris Therapeutics Inc ACRS
33 GF Score
Price $6.01
GF Value $0.41
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Insider Ownership?

Aclaris Therapeutics ACRS -2.28% 33 Insider Ownership is 3.16 % as of Aug. 29, 2026. GuruFocus rates ACRS with a GF Score™ of 33/100 and a GF Value™ of $0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aclaris Therapeutics's insider ownership is 3.16%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aclaris Therapeutics's Institutional Ownership is 79.25%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aclaris Therapeutics's Float Percentage Of Total Shares Outstanding is 88.10%.

Aclaris Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Aclaris Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics Insider Ownership Chart

Aclaris Therapeutics Historical Data

The historical data trend for Aclaris Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 3.72 3.72 3.72 3.72 3.72 3.87 3.58 3.11 3.16 3.16
ACRS
33GF Score
Aclaris Therapeutics Inc ACRS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aclaris Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 3.16 % mean?
Aclaris Therapeutics (ACRS) has a Insider Ownership of 3.16 % as of Aug. 29, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aclaris Therapeutics and its competitors.
Is Aclaris Therapeutics' Insider Ownership too high?
Aclaris Therapeutics' current Insider Ownership is 3.16 %. Overall, Aclaris Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Insider Ownership compare to FTH and AURA?
Aclaris Therapeutics' Insider Ownership of 3.16 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current Insider Ownership is 3.16 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.41, compared to a current price of $6.01 — trading 1365.9% above its estimated fair value. The current Insider Ownership is 3.16 %. Aclaris Therapeutics' overall GF Score™ is 33/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current Insider Ownership is 3.16 % as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aclaris Therapeutics (ACRS) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of $6.01 is trading 1365.9% above its estimated GF Value™ of $0.41. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for ACRS:

  • Insider Ownership: 3.16 %
  • GF Value™: $0.41 vs. price of $6.01 (1365.9% above fair value)
  • GF Score™: 33/100 with 8 warning signs

No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges 0H8T:UK8AT:Germany
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
33GF Score

Get the complete analysis for ACRS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.01
Price
$0.41
GF Value